Literature DB >> 25827863

Survival rates, prognostic factors and treatment of anaplastic meningiomas.

Xiaoyu Cao1, Shuyu Hao1, Zhen Wu1, Liang Wang1, Guijun Jia1, Liwei Zhang1, Junting Zhang2.   

Abstract

Intracranial anaplastic meningioma is a malignant type of meningioma with a high rate of recurrence and death. Given its rarity, minimal information regarding this tumour is available. Thus, we studied a series of patients with anaplastic meningiomas and analysed the survival rates, prognostic factors and treatment methods associated with these patients. Forty-three anaplastic meningioma cases treated at our hospital between July 2002 and June 2012 were compiled into a single database used to summarise the clinical characteristics from a retrospective review of patient records. Progression free survival (PFS) and overall survival (OS) were analysed as a function of each possible prognostic factor. The 1, 3 and 5 year PFS rates were 90.7%, 51.3%, and 37.0%, respectively, whereas the corresponding values of OS rates were 95.3%, 68.0% and 49.2%, respectively. A number of factors were selected to analyse association with prognosis. Simpson Grade I and II resections exhibited increased PFS rates and radiotherapy improved the OS rate in anaplastic meningiomas. Tumours with homogeneous contrast enhancement on MRI were associated with increased PFS and OS. Sex, age, tumour location, first or transformed anaplastic tumour, pre-operative Karnofsky Performance Scores, tumour volumes and bone involvement had no significant effect on either PFS or OS. MRI homogeneous contrast may be a useful prognostic factor and surgery followed by radiotherapy is recommended for the treatment of anaplastic meningiomas.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaplastic meningioma; Prognostic factors; Survival; Treatment

Mesh:

Year:  2015        PMID: 25827863     DOI: 10.1016/j.jocn.2014.11.022

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  10 in total

1.  Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Authors:  Amber J Giles; Shuyu Hao; Michelle Padget; Hua Song; Wei Zhang; John Lynes; Victoria Sanchez; Yang Liu; Jinkyu Jung; Xiaoyu Cao; Rika Fujii; Randy Jensen; David Gillespie; Jeffrey Schlom; Mark R Gilbert; Edjah K Nduom; Chunzhang Yang; John H Lee; Patrick Soon-Shiong; James W Hodge; Deric M Park
Journal:  JCI Insight       Date:  2019-10-17

2.  Papillary meningioma of the central nervous system: a SEER database analysis.

Authors:  Fujun Liu; Yuan Tian; Liangxue Zhou
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

3.  High-precision radiotherapy for meningiomas : Long-term results and patient-reported outcome (PRO).

Authors:  Kerstin A Kessel; Hanna Fischer; Markus Oechnser; Claus Zimmer; Bernhard Meyer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-06-15       Impact factor: 3.621

4.  The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value?

Authors:  Kira Marie Voß; Dorothee Cäcilia Spille; Cristina Sauerland; Eric Suero Molina; Caroline Brokinkel; Werner Paulus; Walter Stummer; Markus Holling; Astrid Jeibmann; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2017-05-19       Impact factor: 4.130

5.  Trends in the Management Paradigms of Intracranial Meningioma.

Authors:  Zaid Aljuboori; Ahmad Alhourani; Shiao Woo; Eyas Hattab; Mehran Yusuf; Megan Nelson; Norberto Andaluz; Dale Ding; Jesse Savage; Brian Williams
Journal:  J Neurol Surg B Skull Base       Date:  2019-09-17

6.  Landscape of genetic variants in sporadic meningiomas captured with clinical genomics.

Authors:  Nathan K Leclair; Erica Shen; Qian Wu; Leo Wolansky; Kevin Becker; Lei Li; Ketan R Bulsara
Journal:  Acta Neurochir (Wien)       Date:  2022-07-26       Impact factor: 2.816

7.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

8.  Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies.

Authors:  Ahmad A Nazem; Jacob Ruzevick; Manuel J Ferreira
Journal:  Oncotarget       Date:  2020-12-08

9.  A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1.

Authors:  Yuxuan Deng; Boyi Hu; Yazhou Miao; Jing Wang; Shaodong Zhang; Hong Wan; Zhen Wu; Yifan Lv; Jie Feng; Nan Ji; Deric Park; Shuyu Hao
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

Review 10.  Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3.

Authors:  Vincenzo Di Nunno; Caterina Giannini; Sofia Asioli; Alfredo Conti; Julia Furtner; Damiano Balestrini; Alicia Tosoni
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.